Physician profile
Sara Sadan
NPI 1831196880
$748.68
in general payments reported to CMS, 2019-2025
10 companies · $74.49 in 2025
The $74.49 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $493 · 2020: $46.52 · 2021: $11.92 · 2022: $43.52 · 2023: $61.99 · 2024: $17.65 · 2025: $74.49.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $111 · Education: $43.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $110.88 |
| Education | $43.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $482.68 | 2019 | |
| Amgen INC. | $46.52 | 2020 | |
| Eisai INC. | $43.52 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $43.25 | 2025 | Enhertu |
| Novartis Pharmaceuticals Corporation | $41.86 | 2023 | |
| Intuitive Surgical, INC. | $31.24 | 2025 | |
| Gilead Sciences, INC. | $29.57 | 2021-2024 | Trodelvy |
| Pfizer INC. | $20.13 | 2023 | |
| Clovis Oncology, INC. | $9.91 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Sadan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.